New Treatment for Hairy Cell Leukemia Granted FDA Approval – Drug for nerve pain boosts high for opioid abusers.

4Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

New Treatment for Hairy Cell Leukemia Granted FDA Approval – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA have approved AstraZeneca’s moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog.1,2 Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL.1

“Lumoxiti fills an unmet need for patients with hairy cell leukemia whose disease has progressed after trying other FDA-approved therapies,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, in a prepared statement.1 “This therapy is the result of important research conducted by the National Cancer Institute that led to the development and clinical trials of this new type of treatment for patients with this rare blood cancer.”

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.